CTOs on the Move

RuiYi

www.ruiyibio.com

 
RuiYi is focused on the discovery and development of novel biologic therapeutics that have the potential to be disruptive globally. In addition to RYI-018 and RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

STRM.BIO

Seattle Biomedical Research Institute

Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mohawk Shared Services

Mohawk Shared Services is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genprex

Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.